Eli Lilly’s ‘game-changing’ diabetes drug could boost the stock, SVB Securities says

- Advertisement -


Eli Lilly’s new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company’s stock, according to SVB Securities.

- Advertisement -

,

- Advertisement -

Credit: www.cnbc.com /

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox